All, | Incident CVD Event | All-cause Mortality | |||
---|---|---|---|---|---|
n = 741 | Yes, n = 177 | No, n = 564 | Died, n = 151 | Survived, n = 590 | |
CVD risk factors | |||||
Hypertension, % | 30.2 | 50.8*** | 23.8 | 38.4* | 28.1 |
Diabetes mellitus, % | 7.2 | 11.0* | 6.1 | 12.8** | 5.8 |
Hyperlipidemia, % | 8.1 | 23.2*** | 3.4 | 11.3 | 7.3 |
Decrease (Δ) in disease measures after 1 year | |||||
ΔCRP, mg/l | 8 (0–32) | 11 (0–34) | 6 (0–31) | 13.5 (0–39) | 6 (0–30) |
ΔESR, mm/h | 16.9 ± 24.4 | 14.8 ± 26.6 | 17.5 ± 23.7 | 17.1 ± 26.9 | 16.8 ± 23.8 |
ΔDAS28 | 1.8 ± 1.6 | 1.7 ± 1.7 | 1.9 ± 1.6 | 1.7 ± 1.8 | 1.9 ± 1.6 |
ΔHAQ | 0.42 ± 0.60 | 0.35 ± 0.61 | 0.44 ± 0.60 | 0.39 ± 0.69 | 0.43 ± 0.58 |
ΔVAS pain, mm | 17.5 ± 29.7 | 16.0 ± 31.1 | 18.0 ± 29.3 | 13.6 ± 32.2 | 18.6 ± 29.0 |
Disease burden (AUC) up to 2 years | |||||
CRP-AUC, mg/l | 26 (15–48.5) | 32.5 (18–56.5)*** | 24.5 (13–45) | 38 (22–65.5)*** | 24 (12.5–44) |
ESR-AUC, mm/h | 38 (22–62) | 46 (27–73)*** | 35 (21–60) | 48 (28–79)*** | 36 (20–60) |
DAS28-AUC | 7.5 ± 2.3 | 7.6 ± 2.3 | 7.4 ± 2.2 | 7.8 ± 2.4 | 7.4 ± 2.2 |
HAQ-AUC | 1.36 ± 1.0 | 1.46 ± 1.09 | 1.33 ± 0.97 | 1.64 ± 1.16*** | 1.29 ± 0.94 |
VAS pain-AUC, mm | 64.6 ± 38.2 | 65.0 ± 37.8 | 64.5 ± 38.4 | 67.2 ± 41.0 | 64.0 ± 37.5 |
HAQ at 2 years | 0.59 ± 0.59 | 0.66 ± 0.62 | 0.57 ± 0.58 | 0.75 ± 0.67*** | 0.55 ± 0.57 |
Regular therapies | |||||
MTX, % | 67.2 | 56.3*** | 70.6 | 59.6* | 69.1 |
GC, % | 51.8 | 58.5* | 49.7 | 57.6 | 50.3 |
Biologic agents, % | 15.9 | 12.4 | 17.1 | 4.6*** | 18.8 |
Values are mean ± SD or medians (IQR) depending on values distribution. P values for between-group differences:
↵* p < 0.05;
↵** p ≤ 0.01;
↵*** p ≤ 0.001. CVD risk factors considered if occurred before the study outcomes or the end of observation. AUC: area under the curve calculated on measurements at baseline, after 1 and 2 years; Δ = decrease in measurements between baseline and the 1-yr assessment; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; DAS28: Disease Activity Score in 28 joints; HAQ: Health Assessment Questionnaire; VAS pain: visual analog scale for pain; MTX: methotrexate; GC: glucocorticoids.